Medication info
Linagliptin Plus XR Tablets 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Linagliptin Plus XR Tablets 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Yellow ovate extended-release film-coated tablets
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202400186 · Approved 2024.01.24 · Insurance code 645406380

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
Determine the dose based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the patient's current doses of linagliptin and extended-release metformin hydrochloride. Because dose adjustment according to renal function is required, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This drug is used in conjunction with diet and exercise to assist patients with type 2 diabetes in controlling their blood glucose levels. Linagliptin and Metformin work together to effectively improve blood sugar levels. Therefore, this drug is used to enhance blood glucose control in patients with type 2 diabetes.

How to take

Adult dose

Determine the dose based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the patient's current doses of linagliptin and extended-release metformin hydrochloride. Because dose adjustment according to renal function is required, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This drug contains Metformin Hydrochloride and Linagliptin as its main components and is an antidiabetic medication that helps regulate blood sugar levels. This drug can rarely cause a metabolic complication known as lactic acidosis, so patients at risk of lactic acidosis should avoid its use. In particular, patients with severely impaired kidney function, type 1 diabetes, or those with acute myocardial infarction or severe infections should not use this drug. This drug may cause hypoglycemia; therefore, blood glucose levels should be carefully monitored when used together with other antidiabetic medications such as insulin or sulfonylureas. It is important to regularly check kidney function during treatment to assess renal status. Rare side effects such as acute pancreatitis or vesicular skin disorders may occur, so if severe abdominal pain or skin abnormalities arise during treatment, advice should be sought from a physician immediately. Prolonged use may lead to vitamin B12 deficiency, so if anemia or neurological symptoms occur, vitamin B12 levels should be checked. This drug should be swallowed whole without crushing, chewing, or breaking it, and the tablet shell may appear in feces, which is normal. Alcohol consumption may increase the risk of lactic acidosis, hence it is advisable to avoid it. Prior to and after tests using iodinated contrast agents, this drug should be temporarily discontinued, and kidney function should be verified. Elderly patients may have a higher risk of declining kidney function, so dose adjustments and monitoring of kidney function are necessary. Women who are pregnant or planning to become pregnant should avoid using this drug, and it is also recommended that breastfeeding women do not use it. When administering this drug with others, the possibility of drug interactions should be considered and discussed with a physician. In cases of overdose, severe side effects such as lactic acidosis may occur, necessitating immediate medical attention.

Side effects

Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemia, taste disturbance, cough, appetite loss, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, similar pemphigus, joint pain associated with severity and disability, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorders, insomnia, depression, bruising, bone contusion, concussion, bone fracture, hand fracture, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, speech disorder, allergic rhinitis, exercise-induced dyspnea, wet cough, runny nose, pulmonary mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, male-pattern baldness, hyperhidrosis, dermatitis, goiter, confusion, nocturia, dermatitis, hypertension, hearing loss, erectile dysfunction, thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to air and moisture, and should be stored in a tightly sealed container. It is also advisable to store it at room temperature, between 1 to 30 degrees Celsius, avoiding extreme heat or cold.

Appearance and packaging

Appearance

Yellow ovate extended-release film-coated tablets

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.